Pharmacist managed diabetes and cardiovascular risk reduction clinic in kidney transplant recipients: Bridging the gap in care transition

Pinelli, Nicole R.; Clark, Lindsey; Carrington, Anne C.; Carrington, Julia L.; Malinzak, Lauren; Patel, Anita

doi:10.1016/j.diabres.2014.09.034

Cited by 14 publications

(20 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Post‐transplant hypertension and hyperglycaemia increase the risk of fatal or non‐fatal cardiovascular events and are highly significant predictors of long‐term kidney graft outcome . Like other studies, our study also found that the pharmacist improved BP control rate and the SBP level among patients …”

Section: Discussionsupporting

confidence: 82%

“…[25][26][27] Like other studies, our study also found that the pharmacist improved BP control rate and the SBP level among patients. 4,28 In China, policy emphasizes the importance of pharmacists.…”

Section: Discussionmentioning

confidence: 99%

“…Several studies had demonstrated the impact of pharmacists on the care of transplant recipients . However, the role of pharmacists in medication management for transplant recipients has only been discussed in certain disease states and aspects like cytomegalovirus (CMV), patient adherence, plasma glucose (PG) levels and blood pressure (BP) levels .…”

Section: Introductionmentioning

confidence: 99%

“…Several studies had demonstrated the impact of pharmacists on the care of transplant recipients. [3][4][5][6][7][8][9] However, the role of pharmacists in medication management for transplant recipients has only been discussed in certain disease states and aspects like cytomegalovirus (CMV), 3,5 patient adherence, 6 plasma glucose (PG) levels 3 and blood pressure (BP) levels. 8,9 There has been no comprehensive study describing the effectiveness of pharmacist-led management of post-transplant medication for kidney transplant recipients on clinical outcomes in inpatient setting.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Impact of pharmacist‐led post‐transplant medication management for kidney transplant recipients: A retrospective pre‐ and post‐intervention study

Yang

Li²,

et al. 2019

J Clin Pharm Ther

View full text Add to dashboard Cite

Summary What is known and objective The roles of pharmacists in medication management for transplant recipients have received limited attention. This study comprehensively assessed the impact of pharmacist‐led post‐transplant medication management. Methods A retrospective pre‐ and post‐intervention study was conducted in the urology ward in a general hospital. Patients receiving kidney transplants from May 2015 to April 2017 were enrolled. Eligible subjects were assigned into two groups (pre‐intervention group and post‐intervention group) according to the date (1 May 2016) when the pharmacist commenced participation in the post‐transplant management for kidney transplant recipients. The outcomes included intervention analysis, cost‐saving effect, outcomes of immunosuppressive drug level monitoring, antibiotic outcomes, safety outcomes, and blood pressure (BP) and plasma glucose (PG) outcomes. Results and discussion A total of 299 patients were admitted to our hospital for kidney transplantation. Two hundred and four patients met inclusion criteria for this study (84 patients were in pre‐intervention group, and 120 patients were in post‐intervention group). Out of 630 pharmacist interventions in the medication order, 97.1% were accepted by the physicians. The average cost of medications per patient decreased from 4661.64 Ren Min Bi (RMB) to 3051.33 RMB. The percentage of patients who maintained tacrolimus (TAC) levels within the target concentration range was higher in the post‐intervention group on post‐operative day (POD) 7 (75.00% vs 87.50%, P = 0.021). There was a significant decrease in antibiotic use density (AUD) and duration of antibiotic treatment in the post‐intervention group. Post‐intervention group showed lower levels in systolic blood pressure (SBP) (141.55 ± 14.62 vs 136.04 ± 13.17, P = 0.01) with higher BP control rate (67.50% vs 90.70%, P = 0.00) on discharge day compared to pre‐intervention group. What is new and conclusion Pharmacists played a comprehensive role in the management of kidney transplant recipients in the inpatient setting, with some evidence of enhanced clinical outcomes.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Impact of pharmacist‐led post‐transplant medication management for kidney transplant recipients: A retrospective pre‐ and post‐intervention study

Yang

Li²,

et al. 2019

J Clin Pharm Ther

View full text Add to dashboard Cite

show abstract

“…przeciwgrzybicze czy preparaty osłonowe dla stosowanej farmakoterapii, zmniejszające kwaśność treści żołądkowej (tj. ranitydyna, famotydyna, czy omeprazol) [13][14][15].…”

Section: Farmakoterapia Pacjentów Po Przeszczepie Nerekunclassified

Identification of the area of services provided by the clinical pharmacist in patient care after kidney transplantation

Gajda¹,

M²,

Fedorowicz³

et al. 2018

Farm Pol.

View full text Add to dashboard Cite

Identification of the area of services provided by the clinical pharmacist in patient care after kidney transplantation • Kidney transplant is a life-extending treatment of choice in end-stage renal disease. Until November 2018, 805 kidney transplantations from deceased donors were performed in Poland and the waiting list for the kidney transplantation procedure is 1176 patients. Optimal care of the patient focuses on: prevention of rejection and organ loss after transplantation, optimization of immunosuppressive therapy, reduction of side effects and toxicity of medication, prolonging long-term survival, as well as providing more cost-effective therapy and cooperation with the patient to improve compliance and medical adherence. This work identifies and describes the area of services provided by the clinical pharmacist (e.g. medication management, cooperation with the transplant team, patient education) as part of patient care after transplantation. The comprehensive goal of the offered pharmaceutical services is to provide high-quality patient care and increase the effectiveness of pharmacotherapy.

show abstract

Observations from a systematic review of pharmacist‐led research in solid organ transplantation: An opinion paper of the American College of Clinical Pharmacy Immunology/Transplantation Practice and Research Network

Pilch

Park

Lichvar

et al. 2020

J Am Coll Clin Pharm

View full text Add to dashboard Cite

Introduction The contributions of transplant pharmacists to clinical and translational research in the United States are ill‐defined and have not been systematically reviewed. Objectives The American College of Clinical Pharmacy Immunology/Transplantation Practice and Research Network conducted a systematic review of available pharmacist‐led research publications involving solid organ transplantation with the intent to quantify and describe pharmacist‐led research endeavors and their changes over time. Methods An electronic search of Scopus was conducted to identify publications in the field of solid organ transplantation by pharmacist authors between January 1, 1975 and May 25, 2017. Articles were excluded if they were written in non‐English languages or originated from non‐US countries. Review articles, case reports, surveys, basic science research, pre‐clinical studies, and non‐transplant research were further excluded. Studies were categorized as one of four phases on the clinical and translational research spectrum, adapted from the Harvard Clinical and Translational Science Center description of a T1 to T4 classification system. Results A total of 10 354 publications were identified by the systematic search with 547 full‐text English‐language publications included in the analysis. Pharmacists served as the first author in 87% of the articles and as the senior author in 67% of the articles. A total of 71% of the articles included more than one pharmacist author. Transplant pharmacists published more studies that employed a retrospective or observational study design (55% and 78%, respectively). A total of 37% of studies were funded. On the spectrum of clinical and translation research, pharmacists were most involved in T3 (translation to practice) research (72%), followed by T2 (translation to patients) research (23%). Conclusions Transplant pharmacists are increasingly represented in the US literature and frequently published across domains. Further demonstrating the relevance of pharmacist‐delivered interventions and outcomes is a critical area of practice focus.

show abstract

Pharmacist managed diabetes and cardiovascular risk reduction clinic in kidney transplant recipients: Bridging the gap in care transition

Cited by 14 publications

References 7 publications

Impact of pharmacist‐led post‐transplant medication management for kidney transplant recipients: A retrospective pre‐ and post‐intervention study

Impact of pharmacist‐led post‐transplant medication management for kidney transplant recipients: A retrospective pre‐ and post‐intervention study

Identification of the area of services provided by the clinical pharmacist in patient care after kidney transplantation

Observations from a systematic review of pharmacist‐led research in solid organ transplantation: An opinion paper of the American College of Clinical Pharmacy Immunology/Transplantation Practice and Research Network

Contact Info

Product

Resources

About